Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study

Riccardo Mei, Lukas Kessler, Kim M. Pabst, Manuel Weber, Christian Schimdkonz, Christoph Rischpler, Helle Damgaard Zacho, Thomas Hope, Sarah M. Schwarzenböck, Martin Allen-Auerbach, Louise Emmett, Justin Ferdinandus, Marcus Unterrainer, Benedikt M. Schaarschmidt, Lale Umutlu, Andrea Farolfi, Paolo Castellucci, Cristina Nanni, Silvi Telo, Stefano Fanti, Ken Herrmann and Wolfgang P. Fendler
Journal of Nuclear Medicine May 2023, 265245; DOI: https://doi.org/10.2967/jnumed.122.265245
Riccardo Mei
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
2Nuclear Medicine Department, IRCCS Azienda Ospedaliero–Universitaria di Bologna, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lukas Kessler
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim M. Pabst
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Weber
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Schimdkonz
4Department of Nuclear Medicine, University Hospital Erlangen, Erlangen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Rischpler
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helle Damgaard Zacho
5Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Hope
6Department of Radiology and Biomedical Imaging, University of California, San Francisco, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah M. Schwarzenböck
7Department of Nuclear Medicine, Rostock University Medical Centre, Rostock, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Allen-Auerbach
8Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
9Institute of Urologic Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise Emmett
10Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, and Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin Ferdinandus
11Department of Internal Medicine I, University of Cologne, Cologne, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus Unterrainer
12Department of Radiology, University Hospital LMU Munich, Munich, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benedikt M. Schaarschmidt
13Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg–Essen, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lale Umutlu
13Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg–Essen, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Farolfi
2Nuclear Medicine Department, IRCCS Azienda Ospedaliero–Universitaria di Bologna, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Castellucci
2Nuclear Medicine Department, IRCCS Azienda Ospedaliero–Universitaria di Bologna, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Nanni
2Nuclear Medicine Department, IRCCS Azienda Ospedaliero–Universitaria di Bologna, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvi Telo
2Nuclear Medicine Department, IRCCS Azienda Ospedaliero–Universitaria di Bologna, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Fanti
2Nuclear Medicine Department, IRCCS Azienda Ospedaliero–Universitaria di Bologna, Bologna, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Herrmann
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang P. Fendler
1Department of Nuclear Medicine, University Hospital Essen, University of Duisburg–Essen, Essen, Germany;
3German Cancer Consortium, Partner Site University Hospital Essen, and German Cancer Research Center, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Visual Abstract

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

68Ga-fibroblast activation protein inhibitors (FAPIs) are promising radiotracers for cancer imaging, with emerging data in the recent years. Nonetheless, the interobserver agreement on 68Ga-FAPI PET/CT study interpretations in cancer patients remains poorly understood. Methods: 68Ga-FAPI PET/CT was performed on 50 patients with various tumor entities (sarcoma [n = 10], colorectal cancer [n = 10], pancreatic adenocarcinoma [n = 10], genitourinary cancer [n = 10], and other types of cancer [n = 10]). Fifteen masked observers reviewed and interpreted the images using a standardized approach for local, local nodal, and metastatic involvement. Observers were grouped by experience as having a low (<30 prior 68Ga-FAPI PET/CT studies; n = 5), intermediate (30–300 studies; n = 5), or high level of experience (>300 studies; n = 5). Two independent readers with a high level of experience and unmasked to clinical information, histopathology, tumor markers, and follow-up imaging (CT/MRI or PET/CT) served as the standard of reference (SOR). Observer groups were compared by overall agreement (percentage of patients matching SOR) and Fleiss κ with mean and corresponding 95% CI. We defined acceptable agreement as a κ value of at least 0.6 (substantial or higher) and acceptable accuracy as at least 80%. Results: Highly experienced observers agreed substantially on all categories (primary tumor: κ = 0.71; 95% CI, 0.71–0.71; local nodal involvement: κ = 0.62; 95% CI, 0.61–0.62; distant metastasis: κ = 0.75; 95% CI, 0.75–0.75), whereas observers with intermediate experience showed substantial agreement on primary tumor (κ = 0.73; 95% CI, 0.73–0.73) and distant metastasis (κ = 0.65; 95% CI, 0.65–0.65) but moderate agreement on local nodal stages (κ = 0.55; 95% CI, 0.55–0.55). Observers with low experience had moderate agreement on all categories (primary tumor: κ = 0.57; 95% CI, 0.57–0.58; local nodal involvement: κ = 0.51; 95% CI, 0.51–0.52; distant metastasis: κ = 0.54; 95% CI, 0.53–0.54). Compared with SOR, the accuracy for readers with high, intermediate, and low experience was 85%, 83%, and 78%, respectively. In summary, only highly experienced readers showed substantial agreement and a diagnostic accuracy of at least 80% in all categories. Conclusion: The interpretation of 68Ga-FAPI PET/CT for cancer imaging had substantial reproducibility and accuracy among highly experienced observers only, especially for local nodal and metastatic assessments. Therefore, for accurate interpretation of different tumor entities and pitfalls, we recommend training or experience with at least 300 representative scans for future clinical readers.

  • cancer imaging
  • FAPI
  • fibroblast activation protein
  • PET
  • interobserver agreement

Footnotes

  • Published online May. 25, 2023.

  • © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (5)
Journal of Nuclear Medicine
Vol. 64, Issue 5
May 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
Riccardo Mei, Lukas Kessler, Kim M. Pabst, Manuel Weber, Christian Schimdkonz, Christoph Rischpler, Helle Damgaard Zacho, Thomas Hope, Sarah M. Schwarzenböck, Martin Allen-Auerbach, Louise Emmett, Justin Ferdinandus, Marcus Unterrainer, Benedikt M. Schaarschmidt, Lale Umutlu, Andrea Farolfi, Paolo Castellucci, Cristina Nanni, Silvi Telo, Stefano Fanti, Ken Herrmann, Wolfgang P. Fendler
Journal of Nuclear Medicine May 2023, 265245; DOI: 10.2967/jnumed.122.265245

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
Riccardo Mei, Lukas Kessler, Kim M. Pabst, Manuel Weber, Christian Schimdkonz, Christoph Rischpler, Helle Damgaard Zacho, Thomas Hope, Sarah M. Schwarzenböck, Martin Allen-Auerbach, Louise Emmett, Justin Ferdinandus, Marcus Unterrainer, Benedikt M. Schaarschmidt, Lale Umutlu, Andrea Farolfi, Paolo Castellucci, Cristina Nanni, Silvi Telo, Stefano Fanti, Ken Herrmann, Wolfgang P. Fendler
Journal of Nuclear Medicine May 2023, 265245; DOI: 10.2967/jnumed.122.265245
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Multicenter Evaluation of Frequency and Impact of Activity Infiltration in PET Imaging, Including Microscale Modeling of Skin-Absorbed Dose
  • Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer
Show more Clinical Investigation

Similar Articles

Keywords

  • cancer imaging
  • FAPI
  • fibroblast activation protein
  • PET
  • interobserver agreement
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire